Overview

Useful For

Carrier screening and diagnosis of 21-hydroxylase deficient congenital adrenal hyperplasia (CAH) in individuals with a personal or family history of 21-hydroxylase deficiency, or as follow-up to positive CAH newborn screens and/or measurement of basal and adrenocorticotropic hormone-1-24 stimulated 17-hydroxyprogesterone, androstenedione, and other adrenal steroid levels.

May be used to identify CYP21A2 mutations in individuals with a suspected diagnosis of 21-hydroxylase deficient CAH when a common mutation panel is negative or only identifies 1 mutation.

In prenatal cases of ambiguous genitalia detected by ultrasound, particularly when the fetus is confirmed XX female by chromosome analysis.

This test ID should also be used for known/familial variant analysis for CYP21A2. Due to the complexity of the CYP21A2 locus, site specific testing for known/familial variants is not offered for this gene.

Genetics Test Information

This test includes Sanger gene sequencing and multiplex ligation-dependent probe amplification to evaluate the CYP21A2 gene for carrier screening and diagnosis of 21-hydroxylase deficient congenital adrenal hyperplasia (CAH).

Highlights

This test aids in carrier screening and diagnosis of 21-hydroxylase deficient congenital adrenal hyperplasia (CAH).

Full gene sequencing and multiplex ligation-dependent probe amplification are used to detect the common pathogenic CYP21A2 variants, CYP21A2 full gene deletions, and rare CYP21A2 variants.

Reflex Tests

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Reporting Name</th>
<th>Available Separately</th>
<th>Always Performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>MATCC</td>
<td>Maternal Cell Contamination, B</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>CULFB</td>
<td>Fibroblast Culture for Genetic Test</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>CULAF</td>
<td>Amniotic Fluid Culture/Genetic Test</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Testing Algorithm

For prenatal specimens only: If amniotic fluid (nonconfluent cultured cells) is received, amniotic fluid culture will be added and charged separately. If chorionic villus specimen (nonconfluent cultured cells) is received, fibroblast culture will be added and charged separately. For any prenatal specimen that is received, maternal cell contamination studies will be added.

Special Instructions

- Informed Consent for Genetic Testing
- CYP21A2 Gene Testing for Congenital Adrenal Hyperplasia Patient Information
Test Definition: CYPZ
CYP21A2 Gene, Full Gene Analysis

- Informed Consent for Genetic Testing (Spanish)

**Method Name**
Polymerase Chain Reaction (PCR) Amplification Followed by DNA Sequence Analysis and Gene Dosage Analysis by Multiplex Ligation-Dependent Probe Amplification (MLPA)

**NY State Available**
Yes

**Specimen**

**Specimen Type**
Varies

**Advisory Information**
This test is a molecular analysis of the *CYP21A2* gene and does not include biochemical analysis of steroids. For biochemical analysis for congenital adrenal hyperplasia (CAH) which includes cortisol, androstenedione and 17-Hydroxyprogesterone, see CAH21 / Congenital Adrenal Hyperplasia (CAH) Profile for 21-Hydroxylase Deficiency.

**Additional Testing Requirements**
All prenatal specimens must be accompanied by a maternal blood specimen; order MATCC / Maternal Cell Contamination, Molecular Analysis on the maternal specimen.

**Shipping Instructions**
Specimen preferred to arrive within 96 hours of collection.

Prenatal specimens can be sent Monday through Thursday and **must be received by 5 p.m. CST on Friday** in order to be processed appropriately.

**Necessary Information**
[CYP21A2 Gene Testing for Congenital Adrenal Hyperplasia Patient Information](T663) is required and available in Special Instructions

**Specimen Required**

**Specimen Type:** Whole Blood

**Container/Tube:**
Preferred: Lavender top (EDTA)

**Specimen Volume:** 3 mL

**Collection Instructions:**
1. Invert several times to mix blood.
2. Send specimen in original tube.

**Prenatal Specimens**
Specimen Type: Amniotic fluid

Container/Tube: Amniotic fluid container

Specimen Volume: 20 mL

Specimen Stability Information: Refrigerated (preferred)/Ambient

Specimen Type: Chorionic villi

Container/Tube: 15-mL tube containing 15 mL of transport media

Specimen Volume: 20 mg

Specimen Stability Information: Refrigerated

Acceptable

Specimen Type: Confluent cultured cells

Container/Tube: T-25 flask

Specimen Volume: 2 flasks

Collection Instructions: Submit confluent cultured cells from another laboratory.

Specimen Stability Information: Ambient (preferred)/Refrigerated

Forms

1. **New York Clients-Informed consent is required.** Document on the request form or electronic order that a copy is on file. The following documents are available in Special Instructions:
   - [Informed Consent for Genetic Testing](#) (T576)
   - [Informed Consent for Genetic Testing-Spanish](#) (T826)

2. If not ordering electronically, complete, print, and send an [Inborn Errors of Metabolism Test Request](#) (T798) with the specimen.

Specimen Minimum Volume

Amniotic Fluid: 10 mL
Blood: 1 mL
Chorionic Villi: 5 mg

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information
Clinical and Interpretive

Clinical Information

Congenital adrenal hyperplasia (CAH), with an incidence rate of 1 in 10,000 to 18,000 live births, is one of the most common inherited syndromes. The condition is characterized by impaired cortisol production due to inherited defects in steroid biosynthesis. The clinical consequences of CAH, besides diminished cortisol production, depend on which enzyme is affected and whether the loss of function is partial or complete.

In greater than 90% of CAH cases, the affected enzyme is 21-steroid hydroxylase, encoded by the CYP21A2 gene located on chromosome 6 within the highly recombinant human histocompatibility complex locus. 21-hydroxylase deficient CAH is inherited in an autosomal recessive pattern and has a spectrum of clinical phenotypes depending upon residual enzyme activity. Excessive adrenal androgen biosynthesis results in varying degrees of virilization. If there is some residual enzyme activity, a non-classical phenotype results, with signs of hyperandrogenism typically starting in later childhood or adolescence. Individuals with severe enzyme deficiency have classical CAH, with prenatal onset of virilization. Classical CAH which is subdivided into simple-virilizing (minimal residual enzyme activity) and salt-wasting (no residual enzyme activity) forms. Patients with salt-wasting CAH have both cortisol and mineral corticosteroid deficiency and are at risk for life-threatening salt-wasting crises if untreated.

Because of its high incidence rate, 21-hydroxylase deficiency is screened for in most US newborn screening programs, typically by measuring 17-hydroxyprogesterone concentrations in blood spots by immunoassay. Confirmation by other testing strategies (eg, LC-MS/MS, CAHBS / Congenital Adrenal Hyperplasia [CAH] Newborn Screening, Blood Spot), or retesting after several weeks, is required for most positive screens because of the high false-positive rates of the immunoassays (due to physiological elevations of 17-hydroxyprogesterone in premature babies and immunoassay cross-reactivity with other steroids). In a small percentage of cases, additional testing will fail to provide a definitive diagnosis. In addition, screening strategies can miss many non-classical cases, which may present later in childhood or adolescence and require more extensive steroid hormone profiling, including testing before and after adrenal stimulation with adrenocorticotropic hormone (ACTH)-1-24.

For these reasons, genetic diagnosis plays an important ancillary role in both classical and non-classical cases. In addition, the high carrier frequency (approximately 1 in 50) for CYP21A2 mutations makes genetic diagnosis important for genetic counseling. Genetic testing can also play a role in prenatal diagnosis of 21-hydroxylase deficiency. However, accurate genetic diagnosis continues to be a challenge because most of the mutations arise from recombination events between CYP21A2 and its highly homologous pseudogene, CYP21A1P (transcriptionally inactive). In particular, partial or complex rearrangements (with or without accompanying gene duplication events), which lead to reciprocal exchanges between gene and pseudogene, can present severe diagnostic challenges. Comprehensive genetic testing strategies must therefore allow accurate assessment of most, or all, known rearrangements and mutations, as well as unequivocal determination of whether the observed changes are located within a potentially transcriptionally active genetic segment. Testing of additional family members is often needed for clarification of genetic test results.

Reference Values

An interpretive report will be provided.
**Interpretation**

All detected alterations will be evaluated according to American College of Medical Genetics and Genomics (ACMG) recommendations. Variants will be classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

**Cautions**

Because of the complexity of the genetic structure of the CYP21A2 locus, and the possibility that a patient's congenital adrenal hyperplasia (CAH) may be due to other gene defects, genetic testing results should be correlated carefully with clinical and biochemical data.

This testing strategy is superior to approaches previously used, but may still miss some complex and large-scale genetic rearrangements or deletions, as well as genetic changes in far upstream or downstream gene-regulatory elements that impair CYP21A2 gene expression. This can lead to false-negative test results.

Rare polymorphisms in primer binding sites can lead to selective allelic drop-out, which can lead to false-negative or false-positive diagnosis.

Patients without genetic evidence for disease-causing CYP21A2 genetic changes may still have CAH, but due to a different enzyme defect. Additional and expanded biochemical steroid profiling is, therefore, recommended if the clinical picture is strongly suggestive of CAH.

**Clinical Reference**


**Performance**

**Method Description**

A combined testing approach involving PCR amplification, bi-directional sequence analysis, and multiplex ligation-dependent probe amplification (MLPA) is used to identify sequence variants and copy number variation within the CYP21A2 gene (GenBank accession number NM_000500; build GRCh37 (hg19)).

Four sets of PCR primer pairs amplify the CYP21A2 gene, the inactive CYP21A1P pseudogene, and the CYP21A2/CYP21A1P and CYP21A1P/CYP21A2 hybrids to determine the presence or absence of amplification product.

Bi-directional full gene sequence analysis, including a portion of the promoter and 3-prime untranslated regions, is then performed on the CYP21A2 gene and the CYP21A2/CYP21A1P hybrid (if present) to test for the presence of sequence variants. Because the CYP21A1P/CYP21A2 hybrid and the CYP21A1P pseudogene are expected to be inactive, sequencing is not performed unless required for interpretation.
MLPA is performed to determine the copy number of the 5-prime and 3-prime regions of the CYP21A2 gene and the CYP21A1P pseudogene. Quantification and comparison of results is used to determine the copy number of the CYP21A2 gene, the CYP21A1P pseudogene, the CYP21A2/CYP21A1P and CYP21A1P/CYP21A2 hybrids. Correlation of results from PCR, bi-directional sequencing, and MLPA is used to determine the CYP21A2 genotype.

This technology cannot always determine the cis/trans status (cis=same chromosome, trans=opposite chromosomes) of the identified genes, rearrangements, or mutations. Family studies of blood relatives might assist in determination of the cis/trans status.(Cradic KW, Grebe SK: A diagnostic sequencing assay for Cyp21 based on promoter activity provides better understanding of gene rearrangements. Abstract. Endocrine Society Annual Meeting, ENDO 2005)

PDF Report
No

Day(s) and Time(s) Test Performed
Performed weekly; Varies

Analytic Time
14 days

Maximum Laboratory Time
21 days

Specimen Retention Time
Whole Blood: 2 weeks (if available) Extracted DNA: 3 months

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information
81405-CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence


Fibroblast Culture for Genetic Test

88233-Tissue culture, skin or solid tissue biopsy (if appropriate)
88240-Cryopreservation (if appropriate)

Amniotic Fluid Culture/Genetic Test

88235-Tissue culture for amniotic fluid (if appropriate)

88240-Cryopreservation (if appropriate)

Maternal Cell Contamination, B

81265-Comparative analysis using Short Tandem Repeat (STR) markers; patient and comparative specimen (eg, pre-transplant recipient and donor germline testing, post-transplant non-hematopoietic recipient germline [eg, buccal swab or other germline tissue sample] and donor testing, twin zygosity testing or maternal cell contamination of fetal cells (if appropriate)

**LOINC® Information**

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYPZ</td>
<td>CYP21A2 Gene, Full Gene Analysis</td>
<td>94197-1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>37488</td>
<td>Result Summary</td>
<td>50397-9</td>
</tr>
<tr>
<td>37489</td>
<td>Result</td>
<td>82939-0</td>
</tr>
<tr>
<td>37490</td>
<td>Interpretation</td>
<td>69047-9</td>
</tr>
<tr>
<td>37491</td>
<td>Additional Information</td>
<td>48767-8</td>
</tr>
<tr>
<td>37492</td>
<td>Specimen</td>
<td>31208-2</td>
</tr>
<tr>
<td>37493</td>
<td>Source</td>
<td>31208-2</td>
</tr>
<tr>
<td>37494</td>
<td>Released By</td>
<td>18771-6</td>
</tr>
</tbody>
</table>